MannKind (MNKD) reported top-level 30-week results from Phase 4 INHALE-3 study, in which additional patients living with type 1 ...

We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers. In this article, we are ...

Lytham Partners, a leading investor relations firm, today announced the schedule for its Fall 2024 Investor Conference taking ...

MannKind Corporation (NASDAQ:MNKD) is a U.S.-based biopharmaceutical company focused on developing and commercializing ...

On Friday, MannKind Corp (MNKD) stock saw a decline, ending the day at $6.6 which represents a decrease of $-0.10 or -1.49% from the prior close of $6.7. The stock opened at $6.7 and touched a low of ...

MannKind Corp (MNKD) stock saw a modest uptick, ending the day at $6.66 which represents a slight increase of $0.10 or 1.52% from the prior close of $6.56. The stock opened at $6.61 and touched a low ...

MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung ...

In this article, we are going to take a look at where MannKind Corporation (NASDAQ:MNKD) stands against the other 52-week high stocks. The start of the US Federal Reserve cutting cycle ushers a ...

Discover MannKind Corp's innovative patent for synthesizing N-protected 3,6-aminoalkyl-2,5-diketopiperazines, enhancing organic chemistry and pharmaceutical advancements.

DANBURY, Conn. - MannKind (NASDAQ:MNKD) Corporation (NASDAQ:MNKD) announced the initiation of a Phase 3 clinical trial in Japan for its Clofazimine Inhalation Suspension, aimed at treating ...